CVL-231 for Schizophrenia: Safety and Drug Levels
About this title
Read the official source — NCT04136873This study evaluated the safety of CVL-231 for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the safety of CVL-231 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Bentonville and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 130
- Sponsor
- Cerevel Therapeutics, LLC
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT04136873
- Official title
Show the full official title
A Phase 1B Trial To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of CVL-231 in Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Bentonville · Little Rock · Lemon Grove
2 more locations
- Long Beach
- Marlton
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety of CVL-231 for people with schizophrenia.
Who is behind this study?
The study sponsor is Cerevel Therapeutics, LLC.
Did this study involve medication?
Yes. The study involved medication, including CVL-231 and Matching Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
